InsidersTradesSigma
Total declarations
Company
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
5
Disclosed sells
0
T+90 hit rate
20%
T+90 mean return
-9.0%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Vitt Daniel, Chief Executive Officer. Officer active across 1 company, notably Immunic, INC.. Aggregated, 5 reports have been logged. Split: 5 buys · 0 sell. Total volume traded: €58k. Activity tracked since 10 August 2021. The latest transaction was filed on 26 February 2024 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations5 total
14,000 shares@ US$1.309529.1% of flowCommon StockSEC:0001193805-24-000282:0
Ideal exit: 22 Nov 2024 (T+270)
8,000 shares@ US$1.349918.1% of flowCommon StockSEC:0001193805-22-001602:0
Ideal exit: 19 Aug 2023 (T+270)
5,000 shares@ US$3.09990.0088% mcap46.8% of flowCommon StockSEC:0001193805-22-000919:0
Ideal exit: 28 Feb 2023 (T+270)
1,000 shares@ US$9.600.0050% mcap26.6% of flowCommon StockSEC:0001193805-21-001161:0
Ideal exit: 7 May 2022 (T+270)
1,000 shares@ US$9.6014.1% of flowCommon StockSEC:0001193805-21-001161
Ideal exit: 7 May 2022 (T+270)
5 of 5 declarations
About Vitt Daniel
Daniel Vitt is the President and CEO of Immunic, Inc. He leads the strategic and business operations of the company, focusing on innovation in the biotechnology sector. His leadership is essential in guiding the company's vision and growth.
